KAMES CAPITAL plc cut its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 703,964 shares of the company’s stock after selling 11,933 shares during the quarter. Johnson & Johnson comprises approximately 2.6% of KAMES CAPITAL plc’s investment portfolio, making the stock its 9th biggest position. KAMES CAPITAL plc’s holdings in Johnson & Johnson were worth $93,141,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Lenox Wealth Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.7% in the 1st quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after acquiring an additional 6 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after acquiring an additional 841 shares during the last quarter. Ullmann Financial Group Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth $186,000. Taylor Wealth Management Partners increased its stake in shares of Johnson & Johnson by 19.8% in the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after acquiring an additional 250 shares during the last quarter. Finally, Foundation Resource Management Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth $204,000. 66.00% of the stock is owned by institutional investors and hedge funds.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
A number of analysts have issued reports on the company. BMO Capital Markets reaffirmed a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research note on Friday, September 1st. UBS AG reaffirmed a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a research note on Thursday, August 31st. Cowen and Company set a $147.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research note on Thursday, August 24th. Jefferies Group LLC set a $145.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research note on Tuesday, August 15th. Finally, J P Morgan Chase & Co raised their target price on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 16th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $134.60.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/17/johnson-johnson-jnj-shares-sold-by-kames-capital-plc.html.
Johnson & Johnson (NYSE JNJ) traded up 0.20% during trading on Friday, reaching $134.45. The company’s stock had a trading volume of 15,522,011 shares. The company has a market capitalization of $360.86 billion, a P/E ratio of 22.75 and a beta of 0.79. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The company’s 50-day moving average is $132.62 and its 200-day moving average is $129.18.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.74 earnings per share. Equities analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. The ex-dividend date was Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.50%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.